Volume 1 Issue 1

Psilocybin Use in the Future Psychiatric Practice: A Comprehensive Review

Anthony Ceman, M.D.

Volume 1 Issue 1

Abstract:

Objective: Psilocybin, the psychoactive compound found in “magic mushrooms,” is currently a Schedule I substance; as such, the United States Federal Drug Administration consider it to have a high potential for abuse and no medical benefit. However, recent research using psilocybin for the treatment of psychiatric disorders has shown that in certain conditions, it may have superior efficacy with fewer adverse effects than current psychotherapeutic agents. A review of the literature was conducted to elucidate the benefits of psilocybin further and explore the possible implication of future clinical use. Search Methods: Pubmed search terms: psilocybin and depression, anxiety, alcohol, alcohol cessation, and mechanism of action, which resulted in 187 articles with 22 being selected for review. Results: Severe studies with smaller sample studies have shown positive results in the use of psilocybin in treatment-resistant depression, anxiety and depression associated with advanced-stage cancer, along with alcohol and tobacco use disorders. Limited, but positive data show possible treatment use in OCD and anxiety disorders.​

  • Facebook Social Icon
  • Instagram

©2019 by The Journal of Psychedelic Psychiatry. Proudly created with Wix.com